KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Common Equity (2016 - 2025)

Historic Common Equity for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Common Equity fell 122.06% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 122.06%. This contributed to the annual value of $1.9 billion for FY2024, which is 261.72% up from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Common Equity stood at $1.9 billion, which was down 122.06% from $1.7 billion recorded in Q2 2025.
  • CRISPR Therapeutics AG's Common Equity's 5-year high stood at $2.6 billion during Q2 2021, with a 5-year trough of $1.7 billion in Q2 2025.
  • For the 5-year period, CRISPR Therapeutics AG's Common Equity averaged around $2.0 billion, with its median value being $1.9 billion (2024).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Common Equity soared by 18592.08% in 2021, and later plummeted by 2224.38% in 2022.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Common Equity stood at $2.4 billion in 2021, then decreased by 21.84% to $1.9 billion in 2022, then increased by 0.39% to $1.9 billion in 2023, then grew by 2.62% to $1.9 billion in 2024, then dropped by 0.83% to $1.9 billion in 2025.
  • Its last three reported values are $1.9 billion in Q3 2025, $1.7 billion for Q2 2025, and $1.8 billion during Q1 2025.